BiotechTube
Epygen Biotech

Epygen Biotech

Cambridge, United States· Est.
epygenbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

Epygen Biotech is a private, US-based biopharmaceutical company founded in 2019, specializing in the development and manufacturing of biosimilar and novel therapeutic proteins. Its pipeline includes programs in oncology (Pegfilgrastim, Bevacizumab), cardiovascular (Recombinant Streptokinase), hormones (Teriparatide), and vaccines (SARS-CoV-2), supported by in-house CDMO capabilities. The company's strategy centers on leveraging its recombinant protein technology platform to produce high-quality, affordable biologics for global markets, though it appears to be in a pre-revenue or early development stage.

OncologyCardiovascularImmune disordersVaccines

Technology Platform

Recombinant protein expression and protein separation/purification platform for developing and manufacturing biosimilars and novel biologics.

Funding History

1
Total raised:$4M
Seed$4M

Opportunities

The global biosimilars market offers a massive opportunity for cost-effective alternatives to expensive biologic drugs, particularly in oncology.
Epygen's integrated CDMO capabilities and cost-advantaged manufacturing in India provide a dual revenue stream and a strategic edge in serving both developed and price-sensitive emerging markets.

Risk Factors

Key risks include the high failure rate and cost of biosimilar/biologic development, intense competition in target markets like Pegfilgrastim and Bevacizumab, reliance on future financing to fund operations, and the operational complexity of running a transcontinental biopharma company.

Competitive Landscape

Epygen competes in the crowded biosimilars arena against large, established generics/biologics firms (e.g., Biocon, Celltrion, Sandoz) and other agile biotechs. Its CDMO services also place it in competition with global contract manufacturers. Differentiation will rely on cost structure, development speed, and manufacturing quality.

More companies in Biologics / Biosimilars →More companies in United States →